Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 ФГБУ Санкт-Пе тер бург ский на уч но-ис сле до ва тель ский пси хо нев ро ло ги че ский ин сти тут им. В.М.Бех те ре ва; 2 Санкт-Пе тер бург ский го су дар ст вен ный ме ди цин ский уни вер си тет им. акад. И.П.Па в ло ва
Список исп. литературыСкрыть список 1. Janssen. Инструкция по применению лекарственного препарата Рисполепт. http://www.janssencilag.ru/content/products/janssen-cilag.ru_ rus//pool_content/Rispolept_tabl.pdf 2. AstraZeneca. Инструкция по применению лекарственного препарата Сероквель® Пролонг. http://www.rlsnet.ru/tn_index_id_46250.htm 3. Elli Lilly. Инструкция по применению лекарственного препарата Зипрекса. http://www.vidal.ru/poisk_preparatov/zyprexa~9991.htm 4. Белоусов Ю.Б., Гуревич К.Г. Клиническая фармакокинетика. Практика дозирования лекарств. М.: Литтерра, 2005; с. 288. 5. Janssen. Инструкция по применению лекарственного препарата Рисполепт Конста. http://www.janssencilag.ru/content/products/janssen-cilag.ru_rus//pool_content/rispolept_consta.pdf 6. Janssen. Инструкция по медицинскому применению препарата Ксеплион. http://www.janssencilag.ru/content/products/janssen-cilag.ru_ rus//pool_content/xeplion.pdf 7. Elli Lilly. Инструкция по применению лекарственного препарата Зипадера. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000890/WC500054429.pdf 8. Eerdekens M et al. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 2004; 70 (1): 91–100. 9. Mannaert E et al. Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration. Encephale 2005; 31 (5 Pt. 1): 609–15. 10. Nyberg S, Farde L, Halldin C. Delayed normalization of central D2-dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings. Arch Gen Psychiat 1997; 54 (10): 953–8. 11. Wistedt B. A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients. Acta Psychiat Scand 1981; 64 (1): 65–84. 12. Harasko van der Meer C et al. Two cases of long term dopamine D2-receptor blockade after depot neuroleptics. J Neural Transm Gen Sect 1993; 94 (3): 217–21. 13. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007; 21 (11): 911–36. 14. Haddad P, Fleischhacker WW. Safety and adverse effects of antipsychotic long-acting injections. In: Antipsychotic long-acting injections. Ed: P.Haddad, T.Lambert, J.Lauriello. Oxford University Press. NY 2011; p. 282. 15. Chue P et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005; 15 (1): 111–7. 16. Kane JM et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiat 2003; 160 (6): 1125–32. 17. Kane JM et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiat 2010; 167 (2): 181–9. 18. Hough D et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2010; 116 (2–3): 107–17. 19. Bloch Y et al. Use of topical application of lidocaine-prilocaine cream to reduce injection-site pain of depot antipsychotics. Psychiatr Serv 2004; 55 (8): 940–1. 20. Burbridge BE. Computed tomographic measurement of gluteal subcutaneous fat thickness in reference to failure of gluteal intramuscular injections. J Can Assoc Radiol 2007; 58 (2): 72–5. 21. Chan VO et al. Intramuscular injections into the buttocks: are they truly intramuscular? Eur J Radiol 2006; 58 (3): 480–4. 22. Adewuya AO et al. Attitude towards antipsychotics among out-patients with schizophrenia in Nigeria. Acta Psychiat Scand 2006; 113 (3): 207–11. 23. Freudenreich O et al. Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiat 2004; 65 (10): 1372–6. 24. Hofer A et al. Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiat 2002; 63 (1): 49–53. 25. Day JC et al. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiat 2005; 62 (7): 717–24. 26. Patel MX, Nikolaou V, David AS. Psychiatrists\' attitudes to maintenance medication for patients with schizophrenia. Psychol Med 2003; 33 (1): 83–9. 27. Pereira S, Pinto R. A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiat Scand 1997; 95 (6): 464–8. 28. Patel MX et al. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J Psychopharmacol 2009; 23 (7): 789–96. 29. Tavcar R, Dernovsek MZ, Zvan V. Choosing antipsychotic maintenance therapy – a naturalistic study. Pharmacopsychiat 2000; 33 (2): 66–71. 30. Lehman AF et al. The schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2003. Schizophr Bull 2004; 30 (2): 193–217. 31. NICE. Core interventions in the treatment and management of schizophrenia in primary and secondary care (update) Clinical guideline 2009. http://www.nice.org.uk/nicemedia/pdf/CG82FullGuideline.pdf 32. RANZCP. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiat 2005; 39 (1–2): 1–30. 33. Robinson DG et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiat 1999; 156 (4): 544–9. 34. Robinson DG et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiat 2004; 161 (3): 473–9. 35. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiat Scand 2002; 106 (4): 286–90. 36. Robinson D et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiat 1999; 56 (3): 241–7. 37. Parellada E et al. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. J Psychopharmacol 2005; 19 (Suppl. 5): 5–14. 38. Lasser RA et al. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness. Ann Clin Psychiat 2007; 19 (2): 65–71. 39. Kim B et al. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuropsychopharmacol Biol Psychiat 2008; 32 (5): 1231–5. 40. Emsley R et al. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol 2008; 28 (2): 210–3. 41. Emsley R et al. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psychopharmacol 2008; 23 (6): 325–31. 42. Emsley R et al. Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study. J Clin Psychiat 2012; 73 (4): e541–7. 43. Valenstein M et al. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiat 2006; 67 (10): 1542–50. 44. Corrigan PW, Liberman RP, Engel JD. From noncompliance to collaboration in the treatment of schizophrenia. Hosp Community Psychiat 1990; 41 (11): 1203–11. 45. Law MR et al. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiat 2008; 69 (1): 47–53. 46. Novick D et al. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiat Res 2010; 176 (2–3): 109–13. 47. Olfson M et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000; 51 (2): 216–22. 48. Tiihonen J et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. Bmj 2006; 333 (7561): 224. 49. Shi L et al. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv 2007; 58 (4): 482–8. 50. Zhu B et al. Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. Psychiat Serv 2008; 59 (3): 315–7. 51. Olivares JM et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiat 2009; 24 (5): 287–96. 52. Tacchi M-J, Scott J. Improving adherence in schizophrenia and bipolar disorders 2005. John Wiley & Sons Ltd 109. 53. Keks NA et al. Long-acting injectable risperidone vs olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised controlled open-label study. Br J Psychiat 2007; 191: 131–9. 54. Bai YM et al. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiat 2007; 68 (8): 1218–25. 55. Leucht C et al. Oral vs depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011; 127 (1–3): 83–92. 56. Brnabic AJ et al. Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study. Int J Clin Pract 2011; 65 (9): 945–53. 57. Davis JM et al. Depot antipsychotic drugs. Place in therapy. Drugs 1994; 47 (5): 741–73. 58. Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiat 2009 (Suppl.); 52: s63–7. 59. Haddad PM, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections vs oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br J Psychiat 2009 (Suppl.): 52: s20–8. 60. Haddad P, Lambert T, Lauriello J. The role of antipsychotic long-acting injections in current practice. In: Antipsychotic long-acting injections. Ed. P.Haddad, T.Lambert, J.Lauriello. Oxford University Press. NY 2011; p. 282. 61. Burton SC. Strategies for improving adherence to second-generation antipsychotics in patients with schizophrenia by increasing ease of use. J Psychiat Pract 2005; 11 (6): 369–78. 62. Rittmannsberger H. The use of drug monotherapy in psychiatric inpatient treatment. Prog Neuropsychopharmacol Biol Psychiat 2002; 26 (3): 547–51. 63. Almond S et al. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiat 2004; 184: 346–51. 64. Knapp M et al. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiat 2004; 184: 509–16. 65. Gaebel W et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacol 2010; 35 (12): 2367–77. 66. Peuskens J et al. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin 2010; 26 (3): 501–9. 67. Lambert T et al. Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. Ann Gen Psychiat 2011; 10: 10. 68. Olivares JM et al. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy 2008; 6 (1): 41–53.